CN102369209A - 制备特异性位点生理活性多肽结合物的方法 - Google Patents
制备特异性位点生理活性多肽结合物的方法 Download PDFInfo
- Publication number
- CN102369209A CN102369209A CN2010800128908A CN201080012890A CN102369209A CN 102369209 A CN102369209 A CN 102369209A CN 2010800128908 A CN2010800128908 A CN 2010800128908A CN 201080012890 A CN201080012890 A CN 201080012890A CN 102369209 A CN102369209 A CN 102369209A
- Authority
- CN
- China
- Prior art keywords
- peptide
- methionin
- active polypeptide
- binding substances
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
反应缓冲液 | 单-聚乙二醇化降钙素-5K的产率(%) |
0.1M NaAc pH 5.2 | 36 |
0.1M NaAc pH 5.2/45% IPA | 51.3 |
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0023953 | 2009-03-20 | ||
KR20090023953 | 2009-03-20 | ||
PCT/KR2010/001674 WO2010107256A2 (en) | 2009-03-20 | 2010-03-18 | Method for preparing a site-specific physiologically active polypeptide conjugate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102369209A true CN102369209A (zh) | 2012-03-07 |
CN102369209B CN102369209B (zh) | 2015-06-10 |
Family
ID=42740133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080012890.8A Active CN102369209B (zh) | 2009-03-20 | 2010-03-18 | 制备特异性位点生理活性多肽结合物的方法 |
Country Status (25)
Country | Link |
---|---|
US (1) | US8895281B2 (zh) |
EP (1) | EP2408800B1 (zh) |
JP (2) | JP5759976B2 (zh) |
KR (1) | KR101164453B1 (zh) |
CN (1) | CN102369209B (zh) |
AR (1) | AR075913A1 (zh) |
AU (1) | AU2010225523B2 (zh) |
BR (1) | BRPI1013626B8 (zh) |
CA (1) | CA2755395C (zh) |
DK (1) | DK2408800T3 (zh) |
ES (1) | ES2587397T3 (zh) |
HK (1) | HK1163120A1 (zh) |
HR (1) | HRP20161055T1 (zh) |
HU (1) | HUE030373T2 (zh) |
IL (1) | IL215165A (zh) |
MX (1) | MX2011009803A (zh) |
MY (1) | MY150536A (zh) |
NZ (1) | NZ595848A (zh) |
PL (1) | PL2408800T3 (zh) |
PT (1) | PT2408800T (zh) |
RU (1) | RU2495881C2 (zh) |
SG (1) | SG174320A1 (zh) |
TW (1) | TWI472342B (zh) |
WO (1) | WO2010107256A2 (zh) |
ZA (1) | ZA201107658B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103732618A (zh) * | 2011-06-10 | 2014-04-16 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
CN103804483A (zh) * | 2014-03-13 | 2014-05-21 | 中国人民解放军第四军医大学 | Orexin-A聚乙二醇化修饰物及其制备方法 |
CN104507492A (zh) * | 2012-07-25 | 2015-04-08 | 韩美药品株式会社 | 治疗高脂血症的包含泌酸调节肽衍生物的组合物 |
CN104918632A (zh) * | 2012-11-06 | 2015-09-16 | 韩美药品株式会社 | 治疗糖尿病或糖胖病的包括胃泌酸调节素类似物的组合物 |
CN106661118A (zh) * | 2014-06-05 | 2017-05-10 | 韩美药品株式会社 | 降低蛋白质和肽的免疫原性的方法 |
US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
US9731031B2 (en) | 2011-06-17 | 2017-08-15 | Hanmi Science Co., Ltd. | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
CN108026143A (zh) * | 2015-07-24 | 2018-05-11 | 韩美药品株式会社 | 制备生理活性多肽缀合物的方法 |
US10233230B2 (en) | 2014-09-16 | 2019-03-19 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
CN109678930A (zh) * | 2018-12-05 | 2019-04-26 | 西北工业大学 | 聚乙二醇修饰的npff及其用途 |
US10513550B2 (en) | 2014-12-30 | 2019-12-24 | Hanmi Pharm Co., Ltd | Glucagon derivatives |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103189388B (zh) * | 2010-10-08 | 2015-05-06 | 国立大学法人京都大学 | 肽衍生物及其用途 |
US9278146B2 (en) | 2010-10-08 | 2016-03-08 | Kyoto University | Peptide derivative and use of the same |
CN102675452B (zh) * | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
CN106928341B (zh) * | 2011-03-30 | 2021-06-01 | 上海仁会生物制药股份有限公司 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
WO2012167251A1 (en) * | 2011-06-02 | 2012-12-06 | Prolor Biotech Inc. | Long-acting glp-1/glucagon receptor agonists |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
EA201492269A1 (ru) | 2012-06-04 | 2016-02-29 | Опко Байолоджикс Лтд. | Пегилированные варианты oxm |
KR20140088837A (ko) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
MX361083B (es) * | 2013-02-26 | 2018-11-27 | Hanmi Pharma Co Ltd | Conjugado de insulina específico de sitio. |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
KR101974305B1 (ko) * | 2018-02-14 | 2019-04-30 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
CN109535244B (zh) * | 2018-12-11 | 2020-12-01 | 上海景峰制药有限公司 | 一种重组人脑利钠肽的纯化方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093823A2 (en) * | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
WO2009011544A2 (en) * | 2007-07-16 | 2009-01-22 | Hanmi Pharmaceutical Co., Ltd. | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
EP0922446A1 (en) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
EP2264064A1 (en) * | 1999-04-30 | 2010-12-22 | Amylin Pharmaceuticals Inc. | Modified exendins and exendin agonists |
WO2002028437A1 (en) * | 2000-10-05 | 2002-04-11 | Ares Trading S.A. | Regioselective liquid phase pegylation |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US8423976B2 (en) * | 2003-03-13 | 2013-04-16 | Northrop Grumman Corporation | Extreme pipeline and optimized reordering technology |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
KR100507796B1 (ko) | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | 생체내 반감기가 증가된 peg-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 |
BRPI0409322B8 (pt) * | 2003-04-11 | 2021-05-25 | Antriabio Inc | método para preparar um conjugado de insulina-polímero |
CA2532340A1 (en) * | 2003-08-21 | 2005-03-03 | Novo Nordisk A/S | Separation of polypeptides comprising a racemized amino acid |
NO20210454A1 (no) * | 2004-11-12 | 2007-06-27 | Bayer Healthcare Llc | Setedirigert modifikasjon av FVIII |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
-
2010
- 2010-03-18 RU RU2011142332/04A patent/RU2495881C2/ru active
- 2010-03-18 BR BRPI1013626A patent/BRPI1013626B8/pt active IP Right Grant
- 2010-03-18 EP EP10753706.0A patent/EP2408800B1/en active Active
- 2010-03-18 MY MYPI2011004374 patent/MY150536A/en unknown
- 2010-03-18 MX MX2011009803A patent/MX2011009803A/es active IP Right Grant
- 2010-03-18 US US13/255,199 patent/US8895281B2/en active Active
- 2010-03-18 HU HUE10753706A patent/HUE030373T2/en unknown
- 2010-03-18 AU AU2010225523A patent/AU2010225523B2/en active Active
- 2010-03-18 DK DK10753706.0T patent/DK2408800T3/en active
- 2010-03-18 CN CN201080012890.8A patent/CN102369209B/zh active Active
- 2010-03-18 JP JP2012500720A patent/JP5759976B2/ja active Active
- 2010-03-18 ES ES10753706.0T patent/ES2587397T3/es active Active
- 2010-03-18 PT PT107537060T patent/PT2408800T/pt unknown
- 2010-03-18 NZ NZ595848A patent/NZ595848A/en not_active IP Right Cessation
- 2010-03-18 WO PCT/KR2010/001674 patent/WO2010107256A2/en active Application Filing
- 2010-03-18 SG SG2011065166A patent/SG174320A1/en unknown
- 2010-03-18 PL PL10753706.0T patent/PL2408800T3/pl unknown
- 2010-03-18 KR KR1020100024312A patent/KR101164453B1/ko active IP Right Grant
- 2010-03-18 CA CA2755395A patent/CA2755395C/en active Active
- 2010-03-19 TW TW99108144A patent/TWI472342B/zh not_active IP Right Cessation
- 2010-03-22 AR ARP100100911A patent/AR075913A1/es not_active Application Discontinuation
-
2011
- 2011-09-15 IL IL215165A patent/IL215165A/en active IP Right Grant
- 2011-10-19 ZA ZA2011/07658A patent/ZA201107658B/en unknown
-
2012
- 2012-04-05 HK HK12103382.6A patent/HK1163120A1/zh not_active IP Right Cessation
-
2015
- 2015-03-02 JP JP2015040382A patent/JP2015127330A/ja not_active Withdrawn
-
2016
- 2016-08-21 HR HRP20161055TT patent/HRP20161055T1/hr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093823A2 (en) * | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
WO2009011544A2 (en) * | 2007-07-16 | 2009-01-22 | Hanmi Pharmaceutical Co., Ltd. | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9765131B2 (en) | 2011-06-10 | 2017-09-19 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
CN103732618A (zh) * | 2011-06-10 | 2014-04-16 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
US10442848B2 (en) | 2011-06-10 | 2019-10-15 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US9522946B2 (en) | 2011-06-10 | 2016-12-20 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US9527898B2 (en) | 2011-06-10 | 2016-12-27 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
CN103732618B (zh) * | 2011-06-10 | 2018-10-09 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
US11872283B2 (en) | 2011-06-17 | 2024-01-16 | Hanmi Science Co., Ltd | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
US10363320B2 (en) | 2011-06-17 | 2019-07-30 | Hanmi Science Co., Ltd. | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
US9731031B2 (en) | 2011-06-17 | 2017-08-15 | Hanmi Science Co., Ltd. | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
CN107854691B (zh) * | 2012-07-25 | 2021-04-09 | 韩美药品株式会社 | 治疗高脂血症的包含泌酸调节肽衍生物的组合物 |
US10493132B2 (en) | 2012-07-25 | 2019-12-03 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
CN107854691A (zh) * | 2012-07-25 | 2018-03-30 | 韩美药品株式会社 | 治疗高脂血症的包含泌酸调节肽衍生物的组合物 |
US9901621B2 (en) | 2012-07-25 | 2018-02-27 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
CN104507492A (zh) * | 2012-07-25 | 2015-04-08 | 韩美药品株式会社 | 治疗高脂血症的包含泌酸调节肽衍生物的组合物 |
US11071785B2 (en) | 2012-11-06 | 2021-07-27 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region |
TWI741218B (zh) * | 2012-11-06 | 2021-10-01 | 南韓商韓美藥品股份有限公司 | 治療糖尿病或糖胖症之包括調酸素類似物之組成物 |
US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
US10279041B2 (en) | 2012-11-06 | 2019-05-07 | Hanmi Pharm Co. Ltd. | Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
US10550168B2 (en) | 2012-11-06 | 2020-02-04 | Hanmi Pharm. Co., Ltd. | Composition for treating diabetes or diabesity comprising oxyntomodulin analog |
TWI645856B (zh) * | 2012-11-06 | 2019-01-01 | 韓美藥品股份有限公司 | 治療糖尿病或糖胖症之包括調酸素類似物之組成物 |
CN104918632A (zh) * | 2012-11-06 | 2015-09-16 | 韩美药品株式会社 | 治疗糖尿病或糖胖病的包括胃泌酸调节素类似物的组合物 |
CN103804483A (zh) * | 2014-03-13 | 2014-05-21 | 中国人民解放军第四军医大学 | Orexin-A聚乙二醇化修饰物及其制备方法 |
CN106661118A (zh) * | 2014-06-05 | 2017-05-10 | 韩美药品株式会社 | 降低蛋白质和肽的免疫原性的方法 |
US10435459B2 (en) | 2014-09-16 | 2019-10-08 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
US10233230B2 (en) | 2014-09-16 | 2019-03-19 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
US10513550B2 (en) | 2014-12-30 | 2019-12-24 | Hanmi Pharm Co., Ltd | Glucagon derivatives |
US11254724B2 (en) | 2014-12-30 | 2022-02-22 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives |
CN108026143A (zh) * | 2015-07-24 | 2018-05-11 | 韩美药品株式会社 | 制备生理活性多肽缀合物的方法 |
US11123436B2 (en) | 2015-07-24 | 2021-09-21 | Hanmi Pharm. Co., Ltd. | Method of preparing physiologically active polypeptide conjugate |
CN108026143B (zh) * | 2015-07-24 | 2022-05-27 | 韩美药品株式会社 | 制备生理活性多肽缀合物的方法 |
CN109678930A (zh) * | 2018-12-05 | 2019-04-26 | 西北工业大学 | 聚乙二醇修饰的npff及其用途 |
CN109678930B (zh) * | 2018-12-05 | 2022-04-29 | 西北工业大学 | 聚乙二醇修饰的npff及其用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102369209B (zh) | 制备特异性位点生理活性多肽结合物的方法 | |
US20220348611A1 (en) | Peptide pharmaceuticals | |
KR20200018526A (ko) | 면역글로불린 단편을 이용한 인슐린 약물 결합체 | |
US10689429B2 (en) | Double-acylated GLP-1 compounds | |
KR20110092253A (ko) | 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물 결합체 | |
AU2023203430A1 (en) | Novel glp-1 analogues | |
EP3924369A1 (en) | Long-acting glp-2 analogs | |
US10202469B2 (en) | Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same | |
KR102438056B1 (ko) | 생리활성폴리펩타이드 결합체의 제조방법 | |
JP2009536670A (ja) | 化合物の細胞浸透性を増加させるための組成物および方法 | |
AU2016273045A1 (en) | Pegylated oxyntomodulin variants | |
JP2021501798A (ja) | アルブミンとの強化された結合親和性を有する医薬構築物 | |
KR20230112568A (ko) | 프로드러그 및 이의 용도 | |
KR20170100936A (ko) | G 단백질 연결 수용체 폴리펩타이드 리간드의 지속형 결합체 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1163120 Country of ref document: HK |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Seoul, South Kerean Applicant after: Hanmi Holdings Co., Ltd. Address before: Seoul, South Kerean Applicant before: Hanmi Pharm Ind Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: HANMI HOLDINGS CO., LTD. TO: HANMI SCIENCE CO., LTD. |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Gyeonggi Do city of East China South Beach Dongtan is Hing Road 550 GA Applicant after: Hanmi Holdings Co., Ltd. Address before: Seoul, South Kerean Applicant before: Hanmi Holdings Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1163120 Country of ref document: HK |